Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

May Daher

Showing results (71-80 of 88) with videos related to

Pageof 9
Sort By:
Nature Medicine|June 26, 2025
Author Correction: Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trialYago Nieto, Pinaki Banerjee, Indreshpal Kaur, et al.
Bone Marrow Transplantation|February 15, 2024
Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxisAlexandre E Malek, Taha Al-Juhaishi, Denái R Milton, et al.
Journal for Immunotherapy of Cancer|June 16, 2023
Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse eventsFaisal Fa'ak, Maryam Buni, Adewunmi Falohun, et al.
Cancer Cell|August 22, 2025
Genome-wide CRISPR screens identify critical targets to enhance CAR-NK cell antitumor potencyAlexander Biederstädt, Rafet Basar, Jeong-Min Park, et al.
Cancer Cell|August 13, 2024
Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPDMayra Shanley, May Daher, Jinzhuang Dou, et al.
Nature Medicine|January 18, 2024
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19<sup>+</sup> B cell tumors: a phase 1/2 trialDavid Marin, Ye Li, Rafet Basar, et al.
Cancer Cell|May 10, 2022
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunityYared Hailemichael, Daniel H Johnson, Noha Abdel-Wahab, et al.
Blood Advances|July 28, 2020
Large-scale GMP-compliant CRISPR-Cas9-mediated deletion of the glucocorticoid receptor in multivirus-specific T cellsRafet Basar, May Daher, Nadima Uprety, et al.
Frontiers in Immunology|May 21, 2021
Metabolic Reprogramming of GMP Grade Cord Tissue Derived Mesenchymal Stem Cells Enhances Their Suppressive Potential in GVHDMayela Mendt, May Daher, Rafet Basar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 30, 2021
Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following AllotransplantationAmanda Olson, Ruitao Lin, David Marin, et al.
Pageof 9

Showing results (71-80 of 88) with videos related to

Sort By:
Pageof 9
Nature Medicine|June 26, 2025
Author Correction: Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trialYago Nieto, Pinaki Banerjee, Indreshpal Kaur, et al.
Bone Marrow Transplantation|February 15, 2024
Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxisAlexandre E Malek, Taha Al-Juhaishi, Denái R Milton, et al.
Journal for Immunotherapy of Cancer|June 16, 2023
Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse eventsFaisal Fa'ak, Maryam Buni, Adewunmi Falohun, et al.
Cancer Cell|August 22, 2025
Genome-wide CRISPR screens identify critical targets to enhance CAR-NK cell antitumor potencyAlexander Biederstädt, Rafet Basar, Jeong-Min Park, et al.
Cancer Cell|August 13, 2024
Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPDMayra Shanley, May Daher, Jinzhuang Dou, et al.
Nature Medicine|January 18, 2024
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19<sup>+</sup> B cell tumors: a phase 1/2 trialDavid Marin, Ye Li, Rafet Basar, et al.
Cancer Cell|May 10, 2022
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunityYared Hailemichael, Daniel H Johnson, Noha Abdel-Wahab, et al.
Blood Advances|July 28, 2020
Large-scale GMP-compliant CRISPR-Cas9-mediated deletion of the glucocorticoid receptor in multivirus-specific T cellsRafet Basar, May Daher, Nadima Uprety, et al.
Frontiers in Immunology|May 21, 2021
Metabolic Reprogramming of GMP Grade Cord Tissue Derived Mesenchymal Stem Cells Enhances Their Suppressive Potential in GVHDMayela Mendt, May Daher, Rafet Basar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 30, 2021
Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following AllotransplantationAmanda Olson, Ruitao Lin, David Marin, et al.
Pageof 9